Aug. 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

View Clearside Biomedical, Inc. (CLSD) current and estimated P/E ratio data provided by Seeking Alpha.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Moreover, CLSD currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises ...

Clearside Biomedical Inc (CLSD) stock saw a decline, ending the day at $1.23 which represents a decrease of $-0.12 or -8.89% from the prior close of $1.35. The stock opened at $1.38 and touched a low ...

The U.S. Department of Education has awarded a $58.9 million grant meant to help young Oklahoma students become better ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

The Louisiana Department of Education (LDOE) has been awarded $70 million through the Comprehensive Literacy State ...

Fintel reports that on August 21, 2024, Chardan Capital initiated coverage of Clearside Biomedical (NasdaqGM:CLSD) with a Buy recommendation. As of August 6, 2024, the average one-year price ...